Oscar Health

Oscar Health’s stock rose to a 52-week high of $34.09 and is currently trading at $33.81. Over the past year the stock gained 68.55%; in the last six months it rose 143% and year-to-date it is up 127%. In the second quarter Oscar Health beat expectations with adjusted earnings of $1.10 per share (expectation $0.37) and revenue of $4.88 billion (expectation $4.73 billion). Analysts currently view the stock as overvalued, according to InvestingPro, and there was a premarket price decline despite the strong quarterly results. » Więcej na de.investing.com

Oscar Health’s stock climbed to a 52-week high of $33.12 and has a market capitalization of $10.17 billion and a P/E ratio of 17.27. Year-to-date the share price is up 110.1%, up 114% since the start of the year, and up 129% over six months. In the second quarter Oscar Health beat expectations with adjusted earnings per share of $1.10 and revenue of $4.88 billion; the company attributes the results to record profitability, improved medical cost trends and tighter cost control. An analysis by InvestingPro currently rates the stock as overvalued. » Więcej na de.investing.com

Oscar Health reported $1 billion net income in the first half of 2026, citing disciplined pricing, operating leverage and AI tools (Oswell) that guided members to lower-cost care and identified pharmacy savings. Management raised full-year 2026 earnings from operations guidance to $500 million–$700 million and expects full-year MLR of 81.5%–82.5%, while forecasting higher churn in H2 as CMS eligibility verifications accelerate. Company noted a $160 million favorable 2025 risk-adjustment true-up, continued SG&A efficiency from its single-platform tech stack, and ongoing CMS reviews with anticipated impacts already reflected in guidance. » Więcej na finance.yahoo.com